Partnership with Sysmex on the Development and Supply of Diagnostic Reagent Raw Materials
First written in FY2023. 2 of 4 entries say "Restated". Latest entry: 2026-05-28.
No other company in this theme has enough history to compare yet.
- 2026-05-28AdvancedFinancial results presentation
「The provision of raw materials for one in vitro diagnostic product has been decided, and adoption for several more products is planned going forward.」
The Company indicated that provision of raw materials for at least 1 in vitro diagnostic product had been decided, with adoption for multiple additional products planned. - FY2025RestatedAnnual report
「We are currently jointly developing antibodies and proteins as candidates for diagnostic-reagent raw materials across several products. Details have not been disclosed due to confidentiality obligations.」
The disclosure continues to state that multiple candidates for diagnostic-reagent raw materials are being jointly developed under the partnership with SYSMEX CORPORATION. - FY2024RestatedAnnual report
「We are currently jointly developing antibodies and proteins as candidates for diagnostic-reagent raw materials across several products. Details have not been disclosed due to confidentiality obligations.」
The partnership with SYSMEX CORPORATION continues to involve the joint development of multiple antibody and protein candidates for diagnostic-reagent raw materials. - FY2023First statedAnnual report
「Through this business partnership, IBL can optimise its distinctive antibody library for measurement platforms including SYSMEX CORPORATION's HISCLTM and supply it as a raw material for diagnostic reagents. It will also use its strengths in antibody development technology to develop antibodies addressing various diagnostic needs in global markets and expand its diagnostic-reagent business through supplies to SYSMEX CORPORATION.」
On 27 June 2022, we entered into a business partnership agreement with SYSMEX CORPORATION for the development of reagent raw materials for the in-vitro diagnostics field. The agreement runs from 1 April 2022 to 31 March 2027, during which we will optimise and supply the antibody library for measurement platforms.